Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)

August 31, 2015 updated by: AIO-Studien-gGmbH

Randomized Three Arm Phase III Trial on Induction Treatment With a Fluoropyrimidine-, Oxaliplatin- and Bevacizumab-based Chemotherapy for 24 Weeks Followed by Maintenance Treatment With a Fluoropyrimidine and Bevacizumab vs. Bevacizumab Alone vs. no Maintenance Treatment and Reinduction in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal Cancer

Investigating the efficacy of maintenance and reinduction treatment or no treatment and watchful waiting in subjects with inoperable or irresectable and non-progressive metastatic colorectal cancer after first line induction treatment for 24 weeks with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy.

The maintenance treatment with capecitabine or 5-FU/folinic acid and bevacizumab will be compared with a maintenance treatment with bevacizumab alone or no maintenance treatment. Reinduction treatment will be done in case of progression.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Chemotherapy and bevacizumab represent a standard of care in treatment of metastatic colorectal cancer. Until now, continuation of chemotherapy - and bevacizumab - represents the standard of care in colorectal cancer treatment. However, since the OPTIMOX1 trial showed an equivalent duration of disease control for a de-escalation / maintenance / reintroduction strategy compared with a treatment until progression strategy for oxaliplatin-based chemotherapy, the question is whether this strategy might apply also to bevacizumab in combination with chemotherapy. Furthermore, with the introduction of bevacizumab, there are new options for a maintenance treatment which should be evaluated.

As the continuation of chemotherapy plus bevacizumab until disease progression has to be regarded as standard of care, the question is whether a de-escalation of treatment intensity or even withdrawal of treatment ("drug holiday") after a certain treatment period will not be inferior with respect to resulting time with tumor control, but allow patients a period with less toxicity and gain of quality of life.

Study Type

Interventional

Enrollment (Actual)

853

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
      • Berlin, Germany, 10623
        • AIO-Studien gGmbH

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Histologically confirmed and inoperable or irresectable metastatic colorectal cancer (stage IV)
  • Measurable lesion according to RECIST measured within 4 weeks prior to registration of the subject for the study

  • Not allowed prior treatments:

    • Previous chemotherapy for metastatic disease (adjuvant therapy for non-metastasized disease is allowed if terminated more than 6 months ago and without recurrence within 6 months after the end of adjuvant treatment)
    • Prior radiation of indicator lesion(s), except for documented progression during radiation and termination of radiotherapy at least 4 weeks prior to entry into the study
  • 18 and over
  • ECOG 0-2

  • Prior and concomitant associated diseases:

    • No past or current history of malignancies except for the indication under this study and curatively treated:

      • Basal and squamous cell carcinoma of the skin
      • in situ carcinoma of the cervix
      • Other malignant disease without recurrence after at least 5 years of follow-up
    • No severe internal disease (insufficiently treated or uncontrolled arterial hypertension, haemoptoe, New York Heart Association (NYHA) grade II or greater congestive heart failure, symptomatic coronary heart disease, myocardial infarction (= < 12 months prior to inclusion), serious cardiac arrhythmia requiring medication, peripheral arterial occlusive disease stage II or greater, uncontrolled severe disease)
    • No history or evidence upon physical examination of CNS disease unless adequately treated (e.g., primary brain tumour, seizure not controlled with standard medical therapy, brain metastases or history of stroke).
    • No pre-existing neuropathy > = grade 1 (NCI CTCAE), except for loss of tendon reflex as the only symptom
    • No interstitial pneumonia or symptomatic fibrosis of the lung
    • No allogenic transplantation requiring immuno-suppressive therapy
    • No severe non-healing wounds, ulcers or bone fractions.
    • No thrombosis or severe bleeding within 6 months prior to entry into the study (except for bleeding of the tumor before its surgical resection) and no evidence of bleeding diathesis or coagulopathy.

  • Laboratory requirements - within 7 days prior to enrollment:

    • Neutrophil count > = 1,500/μl
    • Platelets > = 100,000/μl
    • Hb > = 9g/dl dL (may be transfused to maintain or exceed this level)
    • Serum creatinine clearance > 50ml/min (Cockroft/Gault)
    • Serum total bilirubin: = < 1.5 x UNL
    • AST and ALT = < 2.5 x UNL; = < 5 x UNL in subjects with documented liver metastases
  • Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and aPTT < 1.5 ULN within 7 days prior to registration. The use of full dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks at the time of registration.
  • Laboratory requirements in fertile women, within 2 days prior to treatment: Negative serum pregnancy test

  • Other medication:

    • No concomitant therapy with certain anti-viral medicines (sorivudine and brivudine or analogue compounds).
    • No continuous medication with ASS > 325 mg or NSAIDs, known to inhibit platelet function.

  • Other:

    • No major surgical procedure, open biopsy, nor significant traumatic injury within 28 days prior to study treatment start, nor anticipation of the need for major surgical procedure during the course of the study except for surgery for colorectal cancer with curative intent and central venous line placement for chemotherapy administration, which must be inserted at least 2 days prior to treatment start.
    • No pregnancy or breastfeeding women.
    • No women of child-bearing potential with positive or missing pregnancy test at study entry; post-menopausal women must have been amenorrheic for at least 12 months to be considered of non-child-bearing potential.
    • No sexually active men or women of childbearing potential not willing to use effective means of contraception (intrauterine contraceptive device, implants, injectables, sexual abstinence or vasectomised partner).
    • No subjects with known allergy to the used study drugs or to any of its excipients.
    • No known DPD deficiency.
    • No proteinuria (>1+); if dipstick test of urine exceeds 1+, proteinuria has to be below 1g protein in 24 hours urine.
    • No concomitant treatment with preparations of St. John's wort.
    • No currently or recent (within the 28 days prior to starting study treatment) treatment of another investigational drug or participation in another investigational study.
    • No known grade III/IV allergic reaction against monoclonal antibodies.
    • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.
    • Before subject registration, written informed consent must be given according to ICH/GCP, and national/local regulations. The subject must be competent to comprehend, sign, and date an IEC-approved informed consent form.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Fluoropyrimidine + Bevacizumab
Standard therapy
Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.

Following induction treatment regimen (for maintenance treatment): No maintenance treatment.

Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.

Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab.

Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.

Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy.
Experimental: Bevacizumab monotherapy
Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.

Following induction treatment regimen (for maintenance treatment): No maintenance treatment.

Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.

Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab.

Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.

Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy.
Experimental: No maintenance treatment
Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.

Following induction treatment regimen (for maintenance treatment): No maintenance treatment.

Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.

Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab.

Drug: 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.

Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Time to failure of maintenance and reinduction treatment strategy measured from randomization
Time Frame: From randomization until second progression after reinduction treatment
From randomization until second progression after reinduction treatment

Secondary Outcome Measures

Outcome Measure
Time Frame
TFS, Toxicity, QoL, PFS 1, PFS 2, ORR (first induction), ORR (reind. treatm.), Treatment free interval/duration of maintenance therapy, second. Resection rate, Reasons for discontinuation, OS, Translational research.
Time Frame: From enrollment until second progression after reinduction treatment
From enrollment until second progression after reinduction treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AIO-Studien-gGmbH

Collaborators

Roche Pharma AG

Investigators

  • Principal Investigator: Susanna Hegewisch-Becker, Prof. Dr., Onkologische Schwerpunktpraxis Eppendorf 20249 Hamburg Germany

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2009

Primary Completion (Actual)

December 1, 2014

Study Completion (Actual)

August 1, 2015

Study Registration Dates

First Submitted

August 19, 2009

First Submitted That Met QC Criteria

September 8, 2009

First Posted (Estimate)

September 9, 2009

Study Record Updates

Last Update Posted (Estimate)

September 1, 2015

Last Update Submitted That Met QC Criteria

August 31, 2015

Last Verified

August 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AIO-KRK-0207
  • ML21768
  • EudraCT-Nr.: 2008-007974-39

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Colorectal Neoplasms

Clinical Trials on 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe